Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
REGULATORY
(Update) Chuikyo Agrees to Shed US Price from Foreign Price Adjustment Rule
A subcommittee of the Central Social Insurance Medical Council, or Chuikyo, agreed on January 25 that it will remove US prices from what is called the foreign price adjustment rule, which is currently used to tweak prices of new drugs…
To read the full story
Related Article
- MHLW Lays Out Chuikyo Discussion Timeline for Drug Pricing Overhaul
January 26, 2017
- Industry Wants Simplified Rule, Limited Application for Foreign Price Adjustment: Chuikyo
January 26, 2017
- Chuikyo on Alert for Trump’s Possible Pressure on Drug Front
January 26, 2017
- MHLW Presents Draft Optimal Use Guidelines for Keytruda: Chuikyo
January 25, 2017
REGULATORY
- Pharma Renews Call to Scrap “Spillover,” “Huge-Seller” Rules as FY2026 Talks Enter Final Stretch
December 11, 2025
- Two Bayer/AskBio Gene Therapies Bag Sakigake Designation
December 11, 2025
- Truqap Braced for Price Cut after Cost-Effectiveness Assessment
December 11, 2025
- LDP Lawmakers’ League Urges Continued Coverage for Local Transdermal Analgesics
December 10, 2025
- Senior LDP Lawmakers Call for “Net Plus” in FY2026 Fee, Drug Price Revisions
December 10, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…